108 related articles for article (PubMed ID: 9016602)
41. Eukaryotic topoisomerase II preferentially cleaves alternating purine-pyrimidine repeats.
Spitzner JR; Chung IK; Muller MT
Nucleic Acids Res; 1990 Jan; 18(1):1-11. PubMed ID: 2155393
[TBL] [Abstract][Full Text] [Related]
42. Identification of four GyrA residues involved in the DNA breakage-reunion reaction of DNA gyrase.
Hockings SC; Maxwell A
J Mol Biol; 2002 Apr; 318(2):351-9. PubMed ID: 12051842
[TBL] [Abstract][Full Text] [Related]
43. Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: Structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity.
Tari LW; Trzoss M; Bensen DC; Li X; Chen Z; Lam T; Zhang J; Creighton CJ; Cunningham ML; Kwan B; Stidham M; Shaw KJ; Lightstone FC; Wong SE; Nguyen TB; Nix J; Finn J
Bioorg Med Chem Lett; 2013 Mar; 23(5):1529-36. PubMed ID: 23352267
[TBL] [Abstract][Full Text] [Related]
44. The complex of DNA gyrase and quinolone drugs on DNA forms a barrier to the T7 DNA polymerase replication complex.
Wentzell LM; Maxwell A
J Mol Biol; 2000 Dec; 304(5):779-91. PubMed ID: 11124026
[TBL] [Abstract][Full Text] [Related]
45. Mechanism of DNA gyrase-mediated illegitimate recombination: characterization of Escherichia coli gyrA mutations that confer hyper-recombination phenotype.
Ashizawa Y; Yokochi T; Ogata Y; Shobuike Y; Kato J; Ikeda H
J Mol Biol; 1999 Jun; 289(3):447-58. PubMed ID: 10356321
[TBL] [Abstract][Full Text] [Related]
46. Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drugs is DNA.
Shen LL; Pernet AG
Proc Natl Acad Sci U S A; 1985 Jan; 82(2):307-11. PubMed ID: 2982149
[TBL] [Abstract][Full Text] [Related]
47. Molecular mechanism of topoisomerase poisoning by the peptide antibiotic albicidin.
Michalczyk E; Hommernick K; Behroz I; Kulike M; Pakosz-Stępień Z; Mazurek L; Seidel M; Kunert M; Santos K; von Moeller H; Loll B; Weston JB; Mainz A; Heddle JG; Süssmuth RD; Ghilarov D
Nat Catal; 2023; 6(1):52-67. PubMed ID: 36741192
[TBL] [Abstract][Full Text] [Related]
48. A Fluorescence-Based, T5 Exonuclease-Amplified DNA Cleavage Assay for Discovering Bacterial DNA Gyrase Poisons.
Dias M; Chapagain T; Leng F
bioRxiv; 2023 Oct; ():. PubMed ID: 37904923
[TBL] [Abstract][Full Text] [Related]
49. Non-enzymatic DNA cleavage reaction induced by 5-ethynyluracil in methylamine aqueous solution and application to DNA concatenation.
Ikeda S; Tainaka K; Matsumoto K; Shinohara Y; Ode KL; Susaki EA; Ueda HR
PLoS One; 2014; 9(3):e92369. PubMed ID: 24647759
[TBL] [Abstract][Full Text] [Related]
50. Single-nucleotide-resolution mapping of DNA gyrase cleavage sites across the Escherichia coli genome.
Sutormin D; Rubanova N; Logacheva M; Ghilarov D; Severinov K
Nucleic Acids Res; 2019 Feb; 47(3):1601. PubMed ID: 30624743
[No Abstract] [Full Text] [Related]
51. The pentapeptide-repeat protein, MfpA, interacts with mycobacterial DNA gyrase as a DNA T-segment mimic.
Feng L; Mundy JEA; Stevenson CEM; Mitchenall LA; Lawson DM; Mi K; Maxwell A
Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33836580
[TBL] [Abstract][Full Text] [Related]
52. Exploiting bacterial DNA gyrase as a drug target: current state and perspectives.
Collin F; Karkare S; Maxwell A
Appl Microbiol Biotechnol; 2011 Nov; 92(3):479-97. PubMed ID: 21904817
[TBL] [Abstract][Full Text] [Related]
53. Type IIA topoisomerase inhibition by a new class of antibacterial agents.
Bax BD; Chan PF; Eggleston DS; Fosberry A; Gentry DR; Gorrec F; Giordano I; Hann MM; Hennessy A; Hibbs M; Huang J; Jones E; Jones J; Brown KK; Lewis CJ; May EW; Saunders MR; Singh O; Spitzfaden CE; Shen C; Shillings A; Theobald AJ; Wohlkonig A; Pearson ND; Gwynn MN
Nature; 2010 Aug; 466(7309):935-40. PubMed ID: 20686482
[TBL] [Abstract][Full Text] [Related]
54. Panel of Bacillus subtilis reporter strains indicative of various modes of action.
Hutter B; Fischer C; Jacobi A; Schaab C; Loferer H
Antimicrob Agents Chemother; 2004 Jul; 48(7):2588-94. PubMed ID: 15215113
[TBL] [Abstract][Full Text] [Related]
55. Quinolone-DNA interaction: sequence-dependent binding to single-stranded DNA reflects the interaction within the gyrase-DNA complex.
Noble CG; Barnard FM; Maxwell A
Antimicrob Agents Chemother; 2003 Mar; 47(3):854-62. PubMed ID: 12604512
[TBL] [Abstract][Full Text] [Related]
56. Importance of the fourth alpha-helix within the CAP homology domain of type II topoisomerase for DNA cleavage site recognition and quinolone action.
Strumberg D; Nitiss JL; Dong J; Walker J; Nicklaus MC; Kohn KW; Heddle JG; Maxwell A; Seeber S; Pommier Y
Antimicrob Agents Chemother; 2002 Sep; 46(9):2735-46. PubMed ID: 12183223
[TBL] [Abstract][Full Text] [Related]
57. Quinolone-binding pocket of DNA gyrase: role of GyrB.
Heddle J; Maxwell A
Antimicrob Agents Chemother; 2002 Jun; 46(6):1805-15. PubMed ID: 12019094
[TBL] [Abstract][Full Text] [Related]
58. Gene expression changes triggered by exposure of Haemophilus influenzae to novobiocin or ciprofloxacin: combined transcription and translation analysis.
Gmuender H; Kuratli K; Di Padova K ; Gray CP; Keck W; Evers S
Genome Res; 2001 Jan; 11(1):28-42. PubMed ID: 11156613
[TBL] [Abstract][Full Text] [Related]
59. Sequence specific interaction of Mycobacterium smegmatis topoisomerase I with duplex DNA.
Bhaduri T; Sikder D; Nagaraja V
Nucleic Acids Res; 1998 Apr; 26(7):1668-74. PubMed ID: 9512537
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
